FDA Unveils AI Platform to Modernize

FDA Launches AI Platform Elsa to Enhance Operational Efficiency

• The FDA introduced Elsa, an AI platform reducing task completion time from three days to six minutes.
• Elsa can summarize reports, compare drug labels, and identify high-risk sites while maintaining data security.
• The rollout of Elsa was completed ahead of the June 30 deadline and under budget.
• Elsa is hosted in the FDA’s secure GovCloud environment and does not use industry-submitted data for training.
• This initiative is part of the FDA’s broader effort to integrate AI into its operations.

The FDA has launched Elsa, a generative AI platform that significantly reduces task times and enhances internal workflows. This marks the beginning of several AI initiatives aimed at modernizing the agency’s operations.